Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling.

Coumarin is bioactivated via 3,4-epoxidation resulting in formation of the hepatotoxic o-hydroxyphenylacetaldehyde (oHPA) and detoxified by cytochrome P450 2A6 (CYP2A6) hydroxylation leading to 7-hydroxycoumarin. The present study defines physiologically based biokinetic (PBBK) models to predict liver levels of the toxic oHPA metabolite of coumarin in rats and in human subjects with normal or deficient CYP2A6 catalyzed coumarin 7-hydroxylation. The results reveal that the predicted maximum tissue concentration (C(max)) of oHPA in the liver of wild type human subjects and of subjects deficient in CYP2A6 catalyzed 7-hydroxylation are, respectively, three and one order of magnitude lower than the values predicted for rat liver. Another difference between CYP2A6 deficient and wild type human subjects is a 500-fold difference in the area under the curve 0-24h (AUC(0-24h)) for the time-dependent oHPA liver concentration pointing at a relative higher percentage of the original dose converted in time through this pathway when CYP2A6 is deficient. For wild type human subjects and the subjects with completely deficient coumarin 7-hydroxylation the AUC(0-24h) values for oHPA in the liver are, respectively, three and one order of magnitude lower than that for rat liver. Even when 7-hydroxylation is deficient, the chances on formation of the hepatotoxic oHPA metabolite will be significantly lower in the liver of humans than those expected in the liver of rats when exposed to a similar dose on a body-weight basis. This conclusion should be taken into account when extrapolating data from experimental studies in sensitive animals, i.e., rats, to the general human population.

[1]  C. Diehm,et al.  The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. , 2002, VASA. Zeitschrift fur Gefasskrankheiten.

[2]  J. DeJongh,et al.  A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans , 1997, Archives of Toxicology.

[3]  Paul Tobback,et al.  Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food (AFC) on a request from the Commission , 2008 .

[4]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[5]  M. Andersen,et al.  Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  E. Becker,et al.  Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. , 2003, International journal of clinical pharmacology and therapeutics.

[7]  A. A. Nelson,et al.  Food flavourings and compounds of related structure. II. Subacute and chronic toxicity. , 1967, Food and cosmetics toxicology.

[8]  D. G. Walters,et al.  Identification of o-hydroxyphenylacetaldehyde as a major metabolite of coumarin in rat hepatic microsomes. , 1992, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[9]  J. Freudenstein,et al.  Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. , 2003, International journal of clinical pharmacology and therapeutics.

[10]  J. Fry,et al.  O-hydroxyphenylacetaldehyde: a major novel metabolite of coumarin formed by rat, gerbil and human liver microsomes. , 1991, Biochemical and biophysical research communications.

[11]  D. G. Walters,et al.  Sex and strain differences in mouse hepatic microsomal coumarin 7-hydroxylase activity. , 1994, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  P. Novotny,et al.  Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. , 1999, The New England journal of medicine.

[13]  E. Casalino,et al.  Rat liver glutathione S-transferase activity stimulation following acute cadmium or manganese intoxication. , 2004, Toxicology.

[14]  J. A. Bond,et al.  In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. , 1994, Carcinogenesis.

[15]  A. M. Api,et al.  Comparative metabolism and kinetics of coumarin in mice and rats. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[16]  G. Simon,et al.  Effects of coumarin following perinatal and chronic exposure in Sprague-Dawley rats and CD-1 mice. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[17]  A. Parkinson,et al.  Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. , 1997, Archives of biochemistry and biophysics.

[18]  M L Shuler,et al.  Use of In Vitro Data for Construction of a Physiologically Based Pharmacokinetic Model for Naphthalene in Rats and Mice To Probe Species Differences , 1999, Biotechnology progress.

[19]  D. G. Walters,et al.  Metabolism of coumarin and 7-ethoxycoumarin by rat, mouse, guinea pig, cynomolgus monkey and human precision-cut liver slices. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  S. Born,et al.  o-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[21]  George P Daston,et al.  Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  J. Idle,et al.  A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[23]  D. G. Walters,et al.  Metabolism of [3-14C] coumarin by human liver microsomes. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[25]  M. Metzler,et al.  Possible role of oxygen radicals in cell transformation by diethylstilbestrol and related compounds. , 1986, Carcinogenesis.

[26]  D. Lewis,et al.  Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites. , 1989, Toxicology and Applied Pharmacology.

[27]  B. Lake,et al.  Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  S. Born,et al.  Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  J. Idle,et al.  Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 , 1998, European Journal of Clinical Pharmacology.

[31]  S. Born,et al.  Synthesis and reactivity of coumarin 3,4-epoxide. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[32]  Ginette Truchon,et al.  Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. , 2002, Toxicology letters.

[33]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[34]  M. Elizalde,et al.  Activity of glutathione-S-transferase in rat liver and kidneys after administration of lead or cadmium , 2005, Archives of Toxicology.

[35]  S. Born,et al.  In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  M. Smyth,et al.  Interspecies differences in coumarin metabolism in liver microsomes examined by capillary electrophoresis. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  S P Felter,et al.  A safety assessment of coumarin taking into account species-specificity of toxicokinetics. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.